Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Not yet recruitingOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

September 30, 2026

Conditions

Atopic DermatitisAtopic Dermatitis, UnspecifiedDermatitis, Atopic

Interventions

DRUG

Abrocitinib

Study Drug for Observational Data Collection.